Lumicell Direct Visualization System (DVS)
Lumicell, Inc. · Decision date Nov 25, 2025
What did the FDA approve?
FDA records P230014/S004 as a supplement to PMA P230014, with the supplement type “Special (Immediate Track)”. The recorded decision is approval, dated Nov 25, 2025.
FDA approval order statement
Approval for changes to the labeling including additional caution/warning/guidance statements and updated labeling to address corrective actions taken with respect to breaking or detachment of elastic bands from the device during use.
- Regulatory pathway
- PMA supplement
- Supplement type
- Special (Immediate Track)
- Clinical specialty
- General, Plastic Surgery
- Decision date
- Nov 25, 2025
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
Regulatory record facts
- Identifier
- P230014/S004
- Regulatory pathway
- PMA supplement
- Applicant
- Lumicell, Inc.
- Product code
- SAW
- Decision code
- APPR
- Decision date
- Nov 25, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Fluorescence imaging for breast cancer detection.
- Applicant
- Lumicell, Inc.
- Product code
- SAW
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P230014/S004 received
Application receipt date recorded by FDA.
P230014/S004 · FDA decision
Special (Immediate Track)
Timeline entries are records held by MedtechLedger for P230014. View FDA’s full supplement list.
Related devices and submissions
Explore the linked device profile
No additional submissions with a verified PMA or product-code relationship are linked here.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Lumicell, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 275 Washington St., Suite 200, Newton, MA, 02458
Sources and methodology
- Original FDA record: P230014/S004
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records